Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,263.29
(
-0.12%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 228494

Tuesday, 02/04/2020 4:41:53 PM

Tuesday, February 04, 2020 4:41:53 PM

Post# of 257300
GILD 4Q19 HCV sales=$630M, -6.5% QoQ on a GAAP* basis. The 4Q19 HCV geographic breakdown was: US $337M; EU $151M; RoW $142M. Full-year 2019 HCV sales were $2.87B (consistent with the $2.7-2.9B guidance given in Feb 2019: #msg-146569713).

GILD’s worldwide HCV patient starts in 4Q19 (CC slide #38) increased to 45K from 42K in 3Q19 (an increase of 25K to 28K in the US), implying further price erosion in the market.

--
4Q19 PR:
http://investors.gilead.com/financial-information/quarterly-earnings

CC slides:
http://investors.gilead.com/static-files/36dc002c-bce8-4242-b087-f4e388d6b606

*See explanation in #msg-151900789.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today